Antibiotic-resistant bacteria are a significant public health concern and motivate efforts to develop new classes of antibiotics. One such class of antibiotics is the arylomycins, which target type I signal peptidase (SPase), the enzyme responsible for the release of secreted proteins from their N-terminal leader sequences. Despite the essentiality, conservation, and relative accessibility of SPase, the activity of the arylomycins is limited against some bacteria, including the important human pathogen Staphylococcus aureus. To understand the origins of the limited activity against S. aureus, we characterized the susceptibility of a panel of strains to two arylomycin derivatives, arylomycin A-C 16 and its more potent analog arylomycin M131. We observed a wide range of susceptibilities to the two arylomycins and found that resistant strains were sensitized by cotreatment with tunicamycin, which inhibits the first step of wall teichoic acid synthesis. To further understand how S. aureus responds to the arylomycins, we profiled the transcriptional response of S. aureus NCTC 8325 to growth-inhibitory concentrations of arylomycin M131 and found that it upregulates the cell wall stress stimulon (CWSS) and an operon consisting of a putative transcriptional regulator and three hypothetical proteins. Interestingly, we found that mutations in the putative transcriptional regulator are correlated with resistance, and selection for resistance ex vivo demonstrated that mutations in this gene are sufficient for resistance. The results begin to elucidate how S. aureus copes with secretion stress and how it evolves resistance to the inhibition of SPase.T he widespread use of antibiotics imposes a relentless selection pressure on bacteria that has driven the evolution of multidrug resistance in many pathogens, and novel classes of antibiotics are needed (1, 2). Staphylococcus aureus has emerged as a particular health concern due to its ability to cause a wide range of infections, ranging from superficial lesions such as skin abscesses and wound infections to more systemic and life-threatening conditions such as osteomyelitis, endocarditis, pneumonia, septicemia, and toxinoses. To infect different tissues, S. aureus relies on the secretion of virulence factors that facilitate adhesion and colonization, promote dissemination, facilitate the evasion of the host immune response, and scavenge nutrients and minerals from the environment (3-6). The majority of proteins destined for export out of the cytoplasm are synthesized as preproteins with N-terminal signal peptide sequences, which target them to the general secretory (Sec) pathway (7-9), and these leader peptides ultimately must be removed by the proteolytic activity of type I signal peptidase (SPase) (10).SPase has long been appreciated as a promising target for antibiotic therapy, and a search for inhibitors led to the identification in 2002 of the arylomycin family of natural product lipopeptide antibiotics from a strain of Streptomyces (Fig. 1) (11-13). Despite the essentiali...